Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Fully-automated systems and the need for global approaches should exhort clinical labs to reinvent routine MS analysis?

Rochat B.

Bioanalysis. 2018 Jul 1;10(14):1129-1141. doi: 10.4155/bio-2018-0074. Epub 2018 Jul 10.

PMID:
29989424
2.

LC-HRMS Metabolomics for Untargeted Diagnostic Screening in Clinical Laboratories: A Feasibility Study.

Rochat B, Mohamed R, Sottas PE.

Metabolites. 2018 Jun 15;8(2). pii: E39. doi: 10.3390/metabo8020039.

3.

Proposed Confidence Scale and ID Score in the Identification of Known-Unknown Compounds Using High Resolution MS Data.

Rochat B.

J Am Soc Mass Spectrom. 2017 Apr;28(4):709-723. doi: 10.1007/s13361-016-1556-0. Epub 2017 Jan 23.

PMID:
28116700
4.

Small-Scale Perfusion Bioreactor of Red Blood Cells for Dynamic Studies of Cellular Pathways: Proof-of-Concept.

Prudent M, Stauber F, Rapin A, Hallen S, Pham N, Abonnenc M, Marvin L, Rochat B, Tissot JD, Lion N.

Front Mol Biosci. 2016 Mar 30;3:11. doi: 10.3389/fmolb.2016.00011. eCollection 2016.

5.

Quantitative performance of a quadrupole-orbitrap-MS in targeted LC-MS determinations of small molecules.

Grund B, Marvin L, Rochat B.

J Pharm Biomed Anal. 2016 May 30;124:48-56. doi: 10.1016/j.jpba.2016.02.025. Epub 2016 Feb 21.

PMID:
26928213
6.

Validation of the Mass-Extraction-Window for Quantitative Methods Using Liquid Chromatography High Resolution Mass Spectrometry.

Glauser G, Grund B, Gassner AL, Menin L, Henry H, Bromirski M, Schütz F, McMullen J, Rochat B.

Anal Chem. 2016 Mar 15;88(6):3264-71. doi: 10.1021/acs.analchem.5b04689. Epub 2016 Feb 23.

PMID:
26836506
7.

A Close Look at the Fate of Compounds we are Exposed to.

Rochat B, Bilat J, Grund B.

Chimia (Aarau). 2014 Nov;68(11):818. doi: 10.2533/chimia.2014.818. No abstract available.

PMID:
26508491
8.

Effects of oral supplementation of iron on hepcidin blood concentrations among non-anaemic female blood donors: a randomized controlled trial.

Waldvogel S, Rochat B, Peduzzi D, Vaucher P, Tissot JD, Favrat B.

Vox Sang. 2016 Feb;110(2):166-71. doi: 10.1111/vox.12348. Epub 2015 Sep 22.

PMID:
26394360
9.

Improved investigations in drug safety by more in-depth individual pharmacokinetics using high-resolution mass spectrometry.

Rochat B, Dahmane E, Zaman K, Csajka C.

Ther Drug Monit. 2015 Apr;37(2):141-6. doi: 10.1097/FTD.0000000000000129. No abstract available.

PMID:
25768971
10.

Is there a future for metabotyping in clinical laboratories?

Rochat B.

Bioanalysis. 2015;7(1):5-8. doi: 10.4155/bio.14.268. No abstract available.

11.

Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance.

Narjoz C, Favre A, McMullen J, Kiehl P, Montemurro M, Figg WD, Beaune P, de Waziers I, Rochat B.

PLoS One. 2014 May 12;9(5):e95532. doi: 10.1371/journal.pone.0095532. eCollection 2014.

12.

Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology.

Dahmane E, Boccard J, Csajka C, Rudaz S, Décosterd L, Genin E, Duretz B, Bromirski M, Zaman K, Testa B, Rochat B.

Anal Bioanal Chem. 2014 Apr;406(11):2627-40. doi: 10.1007/s00216-014-7682-2. Epub 2014 Mar 16.

PMID:
24633563
13.

Validation of hepcidin quantification in plasma using LC-HRMS and discovery of a new hepcidin isoform.

Rochat B, Peduzzi D, McMullen J, Favre A, Kottelat E, Favrat B, Tissot JD, Angelillo-Scherrer A, Bromirski M, Waldvogel S.

Bioanalysis. 2013 Oct;5(20):2509-20. doi: 10.4155/bio.13.225.

PMID:
24138624
14.

Metabotype analysis for personalized biology: a new bioanalytical territory for high-resolution MS.

Rochat B, Favre A, Sottas PE.

Bioanalysis. 2013 May;5(10):1149-52. doi: 10.4155/bio.13.79. No abstract available. Erratum in: Bioanalysis. 2013 Jul;5(13):1706. Bertrand, Rochat [corrected to Rochat, Bertrand]; Amelie, Favre [corrected to Favre, Amelie]; Pierre-Edouard, Sottas [corrected to Sottas, Pierre-Edouard].

PMID:
23721437
15.

Ultra-high pressure liquid chromatography-mass spectrometry for plant metabolomics: a systematic comparison of high-resolution quadrupole-time-of-flight and single stage Orbitrap mass spectrometers.

Glauser G, Veyrat N, Rochat B, Wolfender JL, Turlings TC.

J Chromatogr A. 2013 May 31;1292:151-9. doi: 10.1016/j.chroma.2012.12.009. Epub 2012 Dec 13.

PMID:
23274073
16.

The future key role of LC-high-resolution-MS analyses in clinical laboratories: a focus on quantification.

Rochat B, Kottelat E, McMullen J.

Bioanalysis. 2012 Dec;4(24):2939-58. doi: 10.4155/bio.12.243.

PMID:
23244284
17.

Analysis and quantification of vitamin D metabolites in serum by ultra-performance liquid chromatography coupled to tandem mass spectrometry and high-resolution mass spectrometry--a method comparison and validation.

Bruce SJ, Rochat B, Béguin A, Pesse B, Guessous I, Boulat O, Henry H.

Rapid Commun Mass Spectrom. 2013 Jan 15;27(1):200-6. doi: 10.1002/rcm.6439.

PMID:
23239334
18.

Milbemycins: more than efflux inhibitors for fungal pathogens.

Silva LV, Sanguinetti M, Vandeputte P, Torelli R, Rochat B, Sanglard D.

Antimicrob Agents Chemother. 2013 Feb;57(2):873-86. doi: 10.1128/AAC.02040-12. Epub 2012 Dec 3.

19.

Quantitative/qualitative analysis using LC-HRMS: the fundamental step forward for clinical laboratories and clinical practice.

Rochat B.

Bioanalysis. 2012 Jul;4(14):1709-11. doi: 10.4155/bio.12.159. No abstract available.

PMID:
22877215
20.

Comparison between a high-resolution single-stage Orbitrap and a triple quadrupole mass spectrometer for quantitative analyses of drugs.

Henry H, Sobhi HR, Scheibner O, Bromirski M, Nimkar SB, Rochat B.

Rapid Commun Mass Spectrom. 2012 Mar 15;26(5):499-509. doi: 10.1002/rcm.6121.

PMID:
22302489
21.

Generic approach for the sensitive absolute quantification of large undigested peptides in plasma using a particular liquid chromatography-mass spectrometry setup.

Sobhi HR, Vatansever B, Wortmann A, Grouzmann E, Rochat B.

J Chromatogr A. 2011 Nov 25;1218(47):8536-43. doi: 10.1016/j.chroma.2011.09.072. Epub 2011 Oct 1.

PMID:
22018479
22.

Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.

Rochat B, Pascual A, Pesse B, Lamoth F, Sanglard D, Decosterd LA, Bille J, Marchetti O.

Antimicrob Agents Chemother. 2010 Dec;54(12):5074-81. doi: 10.1128/AAC.00022-10. Epub 2010 Oct 4.

23.

Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin.

Decosterd LA, Rochat B, Pesse B, Mercier T, Tissot F, Widmer N, Bille J, Calandra T, Zanolari B, Marchetti O.

Antimicrob Agents Chemother. 2010 Dec;54(12):5303-15. doi: 10.1128/AAC.00404-10. Epub 2010 Sep 20.

24.

Comparison between a linear ion trap and a triple quadruple MS in the sensitive detection of large peptides at femtomole amounts on column.

Vatansever B, Lahrichi SL, Thiocone A, Salluce N, Mathieu M, Grouzmann E, Rochat B.

J Sep Sci. 2010 Aug;33(16):2478-88. doi: 10.1002/jssc.201000157.

PMID:
20589779
25.
26.

Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein.

Abid K, Rochat B, Lassahn PG, Stöcklin R, Michalet S, Brakch N, Aubert JF, Vatansever B, Tella P, De Meester I, Grouzmann E.

J Biol Chem. 2009 Sep 11;284(37):24715-24. doi: 10.1074/jbc.M109.035253. Epub 2009 Jul 20.

27.

Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.

Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal MA, Ris HB, Leyvraz S, Widmer N, Decosterd LA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jul 15;877(22):1982-96. doi: 10.1016/j.jchromb.2009.04.045. Epub 2009 May 13.

PMID:
19505856
28.

Effect of RasGAP N2 fragment-derived peptide on tumor growth in mice.

Michod D, Annibaldi A, Schaefer S, Dapples C, Rochat B, Widmann C.

J Natl Cancer Inst. 2009 Jun 3;101(11):828-32. doi: 10.1093/jnci/djp100. Epub 2009 May 26.

PMID:
19470951
29.

A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine.

Fayet A, Béguin A, Zanolari B, Cruchon S, Guignard N, Telenti A, Cavassini M, Günthard HF, Buclin T, Biollaz J, Rochat B, Decosterd LA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Apr 15;877(11-12):1057-69. doi: 10.1016/j.jchromb.2009.02.057. Epub 2009 Feb 28.

PMID:
19332396
30.

Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry.

Rochat B, Fayet A, Widmer N, Lahrichi SL, Pesse B, Décosterd LA, Biollaz J.

J Mass Spectrom. 2008 Jun;43(6):736-52. doi: 10.1002/jms.1369.

PMID:
18286663
31.

In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1.

Rochat B, Zoete V, Grosdidier A, von Grünigen S, Marull M, Michielin O.

Biopharm Drug Dispos. 2008 Mar;29(2):103-18. doi: 10.1002/bdd.598.

PMID:
18188833
32.

Liquid chromatography-mass spectrometry method for quantification of caspofungin in clinical plasma samples.

Rochat B, Bolay S, Pascual A, Calandra T, Marchetti O.

J Mass Spectrom. 2007 Apr;42(4):440-9.

PMID:
17238239
33.

Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.

Widmer N, Decosterd LA, Csajka C, Leyvraz S, Duchosal MA, Rosselet A, Rochat B, Eap CB, Henry H, Biollaz J, Buclin T.

Br J Clin Pharmacol. 2006 Jul;62(1):97-112. Erratum in: Br J Clin Pharmacol. 2010 Aug;70(2):316.

34.

Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.

Colombo S, Buclin T, Franc C, Guignard N, Khonkarly M, Tarr PE, Rochat B, Biollaz J, Telenti A, Decosterd LA, Cavassini M.

Antivir Ther. 2006;11(1):53-62.

PMID:
16518960
36.

Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term.

Neef M, Ledermann M, Saegesser H, Schneider V, Widmer N, Decosterd LA, Rochat B, Reichen J.

J Hepatol. 2006 Jan;44(1):167-75. Epub 2005 Jul 12.

PMID:
16168515
37.
39.

Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection.

Widmer N, Béguin A, Rochat B, Buclin T, Kovacsovics T, Duchosal MA, Leyvraz S, Rosselet A, Biollaz J, Decosterd LA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Apr 25;803(2):285-92.

PMID:
15063337
40.

Intra-portal injection of 400- microm microcapsules in a large-animal model.

Toso C, Oberholzer J, Ceausoglu I, Ris F, Rochat B, Rehor A, Bucher P, Wandrey C, Schuldt U, Belenger J, Bosco D, Morel P, Hunkeler D.

Transpl Int. 2003 Jun;16(6):405-10. Epub 2003 Mar 20.

PMID:
12819871
41.

Evaluation of recombinant cytochromes P450 activity in metabolic pathways.

Rochat B.

Drug Metab Dispos. 2003 Jan;31(1):145-6; author reply 146. No abstract available.

PMID:
12518763
42.
43.

Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?

Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL.

J Pharmacol Exp Ther. 2001 Feb;296(2):537-41.

PMID:
11160641
44.

Cloning and initial characterization of the human DPYD gene promoter.

Collie-Duguid ES, Johnston SJ, Powrie RH, Milano G, Etienne MC, Rochat B, Watson GC, McLeod HL.

Biochem Biophys Res Commun. 2000 Apr 29;271(1):28-35.

PMID:
10777676
45.

Drug disposition and targeting. Transport across the blood-brain barrier.

Rochat B, Audus KL.

Pharm Biotechnol. 1999;12:181-200. Review. No abstract available.

PMID:
10742975
46.

Human CYP2B6: expression, inducibility and catalytic activities.

Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, de Waziers I.

Pharmacogenetics. 1999 Jun;9(3):295-306.

PMID:
10471061
47.

Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium.

Rochat B, Baumann P, Audus KL.

Brain Res. 1999 Jun 12;831(1-2):229-36.

PMID:
10412001
48.
49.

Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes.

Rochat B, Amey M, Gillet M, Meyer UA, Baumann P.

Pharmacogenetics. 1997 Feb;7(1):1-10.

PMID:
9110356
50.

Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation.

Bondolfi G, Chautems C, Rochat B, Bertschy G, Baumann P.

Psychopharmacology (Berl). 1996 Dec;128(4):421-5.

PMID:
8986013

Supplemental Content

Loading ...
Support Center